Navigation Links
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
Date:9/4/2012

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at four investor conferences during the first two weeks of September. These four corporate presentations will be webcast.

Friday, September 7th at 8:30 a.m Eastern Time: NewsMakers in the Biotech Industry Conference in New York City

Monday, September 10th at 11:15 a.m. Eastern Time: Rodman & Renshaw Annual Global Investment Conference in New York City

Wednesday, September 12th at 10:55 a.m. Eastern Time: Morgan Stanley Global Healthcare Conference in New York City

Thursday, September 13th at 1:45 p.m. London Time: Bank of America Merrill Lynch Global Healthcare Conference in London

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after each event.

Additionally, on Wednesday, September 5th at 4:00 p.m. Eastern Time, Orexigen management will participate in a panel discussion at the Citi 7th Annual Biotech Day event. This event will not be webcast.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.  The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Co
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
2. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
3. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
4. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
5. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA ... that its common shares have been approved for listing and ... "EPIX". ESSA will begin trading on NASDAQ on ... the TSX Venture Exchange under the symbol "EPI". ... on the NASDAQ, each of the Company,s outstanding special warrants ...
(Date:7/2/2015)... 2015  Before you head outdoors with your family to ... safe and healthy. Take steps to protect yourself from the ... Protect Your Skin From the Sun ... your risk of skin cancer. To protect your skin from ... especially during midday hours. Wear a hat with a wide ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) has announced ... Application, End-User & by Region - Global Trends & Forecast ... market is projected to reach about $2.5 Million by 2020, ... rising opportunities in countries such as India ... , and Brazil . In 2013, the ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3
... 16 Westside Medical Associates of Los Angeles ... announce the benefit of early positron emission tomography ... treatable phase. According to Dr. Norman Lepor , Professor of ... and Co-director of Imaging at WMI, "the research investigators at the ...
... American pharmaceutical manufacturer Alpharma Inc. has agreed to pay ... in connection with the marketing of the morphine-based drug, Kadian, ... between January 1, 2000 and December 29, ... to promote or prescribe Kadian, and made misrepresentations about the ...
Cached Medicine Technology:Early Identification of Alzheimer's Disease With PET Scan 2Early Identification of Alzheimer's Disease With PET Scan 3Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national chief nursing officer ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are great for documenting memories. , Almost every smartphone has an incredibly powerful camera ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Report,with the Securities and Exchange Commission. Consolidated gross ... 2008 were $6,121,632 compared,to $5,713,761 for the same ... strong growth of the over-the-counter (OTC) product line ...
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... ,magic bullet, to help miilions of children in ... News) -- A new compound that may lead to ... by researchers at the University of Texas Health Science ... especially important for developing countries, where diarrhea is a ...
... a doctor could get a lot longer if the current ... increase soon, according to a new University of Missouri study. ... the MU School of Medicine, and his research team found ... 44,000 family physicians and general internists in less than 20 ...
... blood tests for breast, ovarian cancers, HERNDON, ... (CIT), a state-chartered non-profit, announced today,that its GAP ... of Funds, made,a $100,000 early-stage investment in OTraces, ... accurate and sensitive blood screening,tests for breast and ...
... in less than 90 seconds ... Varian Medical Systems, DECATUR, Ill., June 17 Decatur ... third in the,United States, to treat a cancer patient using ... John Hosler, an,85-year-old prostate cancer patient, received his treatment in ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 2Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 4Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 5Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:CIT GAP Funds Invests in OTraces, Inc. 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: